ClinicalTrials.gg
RecruitingNCT07629726Updated Aug 7, 2026

A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

A Phase 1/2 interventional study of KK2430 in Hematologic Neoplasms, sponsored by Kyowa Kirin Co., Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.

02

Conditions studied

  • Hematologic Neoplasms
03

In context

Hematologic Neoplasms

1,444 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.

This study's planned enrollment of 72 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 18 years of age at the time of signing the .
  • At least 1 measurable diseases based on CT scan or MRI
  • Renal function values
  • Participants who have an PS score of 0, 1 or 2.
  • Be willing to provide a fresh tissue taken at current relapse at screening period.
  • Meet laboratory values at Screening i.e., ANC, , Corrected serum calcium, and ALT, Total etc
  • use by [men and women] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Women of and fertile men must agree to use highly effective contraceptive methods • At least 1 measurable diseases based on CT scan or MRI
  • Capable of giving signed informed consent
  • Health Information Access: Capable of providing access to personal health information via HIPAA authorization (US only).
  • Legal Status: Not under any administrative or legal supervision or institutionalization due to regulatory or juridical order.

Exclusion criteria

Exclusion Criteria:

  • Medical Conditions
  • History of prior allogenic transplant.
  • Presence of Grade 2 peripheral neuropathy with pain.
  • Impaired cardiac function or cardiac disease at Screening
  • Known active CNS involvement or clinical signs of meningeal involvement.
  • Evidence of infection.
  • Active chronic / infection,
  • Participants with positive anti-HBc must have a negative HBV-DNA quantification test result to be enrolled.
  • Receipt of any anti-tumor therapy within three weeks or at least five half-lives prior to the Screening visit, whichever is shorter.
  • Toxicities from prior anticancer therapies that have not resolved to Grade 1 or less except for abnormal clinical values alopecia and peripheral neuropathy (participants with Grade 1 or 2 neuropathy without pain are eligible for enrollment).
  • Use of systemic exceeding 10 mg/day of prednisone or equivalent within 14 days prior to the first dose
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    2430-001 Part 1

    KK2430 intravenous administration (including placebo)

    Drug: KK2430

Interventions

  • DrugKK2430

    KK2430 administered intravenously

06

What researchers measure

Primary outcomes

  1. Dose Level Toxicity (DLT)

    Number of Subjects Experiencing DLT; DLTs will be evaluated according to NCI-CTCAE Version 6.0.

    Time frame: Endpoint 28 days after first dose

  2. Adverse Events (AEs)

    Number of participants with treatment-related adverse events as assessed by CTCAE v6.0 (all 72 potentially treated subjects)

    Time frame: Signing of ICF through study completion for an average of 1.5 years

  3. Pregnancy Test

    Presence of hCG hormone

    Time frame: Screening through study completion, an average of 1.5 years

  4. ECG QT Interval

    Duration in ms

    Time frame: Treatment period, an average of 3months

  5. ECG QRS Interval

    Duration in ms

    Time frame: Treatment period, an average of 3months

  6. Vital Sign Measurements

    Axillary body temperature; Degrees Celsius

    Time frame: Treatment period, an average of 3 months

  7. Vital Sign Measurements

    Pulse Rate; beats per minute

    Time frame: Treatment period, an average of 3 months

  8. Vital Sign Measurements

    Respiratory rate; breaths per minute

    Time frame: Treatment period, an average of 3 months

  9. Vital Sign Measurements

    Systolic/Diastolic blood pressure; mm Hg

    Time frame: Treatment period, an average of 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07629726
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Aug 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Kyowa Kirin, Inc.
Contact
KKD.Clinical.82@kyowakirin.com
+1-609-919-1100

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion